Breaking Finance News

A statement released earlier today by RBC Capital about Gilead Sciences (NASDAQ:GILD) raises the target price to $94.00

Yesterday Gilead Sciences (NASDAQ:GILD) traded 1.08% higher at $82.28. The company’s 50-day moving average is $76.95 and its 200-day moving average is $70.12. The last closing price is up 18.63% from the 200-day moving average, compared to the S&P 500 which has increased 0.04% over the same time period. 4,609,352 shares of the stock traded hands, down from an average trading volume of 10,144,300

Gilead Sciences (NASDAQ:GILD) had its target bumped up to $94.00 by RBC Capital in an issued report announced 9/15/2017. The bumped up target suggests a potential upside of 0.14% based on the company's last closing price.

Previously on 09/05/2017, Wells Fargo reported on Gilead Sciences (NASDAQ:GILD) increased the target price from $73.00 to $81.00. At the time, this indicated a possible downside of -0.03%.

See Chart Below

Gilead Sciences (NASDAQ:GILD)

Gilead Sciences has a 52 week low of $63.76 and a 52 week high of $86.27 with a P/E ratio of 9.03 The company’s market cap is currently $0.

In addition to RBC Capital reporting its stock price target, a total of 19 brokers have issued a report on the company. The average stock price target is $111.05 with 7 brokers rating the stock a strong buy, 9 brokers rating the stock a buy, 9 brokers rating the stock a hold, 0 brokers rating the stock a underperform, and finally 0 brokers rating the stock a sell.

General Information About Gilead Sciences (NASDAQ:GILD)

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company's portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions. Its products for HIV/AIDS patients include Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Truvada, Emtriva, Tybost and Vitekta. Its products for patients with liver diseases include Vemlidy, Epclusa, Harvoni, Sovaldi, Viread and Hepsera. It offers Zydelig to patients with hematology/oncology diseases. Its products for patients with various cardiovascular diseases include Letairis, Ranexa and Lexiscan. Its products for various inflammation/respiratory diseases include Cayston and Tamiflu. It had operations in more than 30 countries, as of December 31, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.